by quantities of trypsin that have no observable effect on actin and tropomyosin.
The purified 120000-Mr protein binds tightly to actin and tropomyosin-actin. It has very little effect on the activity of a skeletal myosin/VSM actin system, but when VSM tropomyosin is present it is a potent inhibitor of the ATPase. Inhibition of up to 90% has been obtained with stoichiometries as low as one 120000-Mr protein per 20-3OVSM actin monomers (Fig. 2c) . Thus the 120000-Mr protein can account for the inhibitory part of the regulatory mechanism; it is, however, usually CaZ + insensitive. A number of smooth-muscle inhibitory proteins have been reported from other sources, though they are of lower molecular weight and may represent fragments of a 120000-Mr protein (reviewed in Marston, 1983) .
In the intact VSM thin-filament regulatory system there is a Ca2+-dependent release of inhibition (Fig. 2a) . In skeletal muscle this function is performed by troponin C. VSM thin-filament preparations contain rather small quantities of proteins resembling troponin-C or calmodulin and it is conceivable that such a protein has been largely lost during preparation. The 120000-Mr protein binds to a calmodulin affinity column in Ca2 + and is released by EGTA so it has the capacity for interaction with a calcium-binding protein. Affinity-column methods are being used to try and recover calcium-binding proteins from VSM preparations.
We have been able to reconstitute a functional Ca2 + regulated thin filament using just four proteins, skeletal muscle actin, VSM tropopmyosin, VSM 120000-Mr protein and brain calmodulin, as Ca2 +-binding proteins (Fig. 26) . This demonstrates in principle the mechanism of Ca2 +-dependent regulation of the VSM thin filament. The 120000-Mr protein inhibits actin, tropomyosin propagates the effect over a large number of actin monomers and Ca2 +<alcium-binding protein complex binds to the 120000 Mr-protein, relieving the inhibition. There are as yet practical difficulties in demonstrating a calcium-sensitive system using all VSM proteins. Under our experimental conditions the 120000-Mr protein binds VSM actin + tropomyosin very tightly indeed (K = 108-109M-1) and inhibition cannot be relieved by brain calmodulin. It is likely that a change of experimental conditions or a native CaZ +-binding protein is required. A similar regulatory mechanism has been proposed for gizzard thin filaments (Kakiuchi & Sobue, 1983) . CaZ + regulation of the whole contractile apparatus and the con-
trol of hypertension
Regulation of the whole contractile apparatus involving multiple Ca2 +-dependent systems is likely to be complex and studies have made little headway in sorting things out. The myosin-phosphorylation system has been investigated in intact blood vessels and it now appears that there is a good correlation between level of myosin phosphorylation and contraction velocity under many conditions but a lack of correlation with the isometric tension in prolonged contractures (Murphy, 1982) . This necessitates the involvement of the other regulatory systems (direct Ca2+ binding to myosin and the thin-filament system). There is as yet no data concerning any changes in these systems which might occur in various forms of hypertension. As for control of hypertension, the biochemical studies have identified proteins which might be targets for drugs (calmodulin, myosin kinase, 120000 M, protein), but there is likely to be a problem of specificity. Regulatory systems in all smooth muscles seem rather similar.
$ To whom correspondence should be addressed. of the rabbit. On intravenous infusion it raised blood pressure in test rabbits. They named the material 'renin' and speculated that it was formed in the kidney, then released into blood where as a chemical messenger it produced an effect at a distance constricting peripheral vessels and thereby raising blood pressure. Their speculation is the subject of this review.
The enzymic nature of renin was not recognized until 1939 (see Pickering, 1968) . It is an aspartyl protease formed in the juxtaglomerular apparatus of the renin cortex, mainly in the afferent glomerular arteriole. Immunoperoxidase techniques stain positively both storage granules and endoplasmic reticulum in the juxtaglomerular cells, suggesting that renin is synthesized as well as stored in these cells (Lindop et al., 1983) . Renal renin exists in active and inactive forms. The review by Inagami et al. (1984) in this Colloquium deals with the chemistry of renin.
Active and inactive forms of the enzyme are released from the kidney into blood. In man active renin cleaves a Leu-Val bond in the N-terminal sequence of a plasma protein substrate to produce the decapeptide, angiotensin I (Tewksbury et al., 1981) . The scissile bond in the corresponding substrates for horse pig and rat renin is Leu-Leu (Skeggs et al., 1957) . Angiotensin I is largely inactive biologically, but undergoes rapid enzymic conversion to the active octapeptide, angiotensin 11. All components of this mechanism, renin, renin-substrate, angiotensin I, converting enzyme and angiotensin 11, circulate in plasma .
Renin. angwtensin II and blood pressure
Apart from its ability to raise blood pressure, angiotensin I1 has a very wide range of pharmacological effects (see Brown et al., 1979) : on the kidney, on the central and peripheral nervous systems and on the secretion of corticosteroids, catecholamines, vasopressin and probably corticotrophin. The existence of these pharmacological effects is not in question. Doubt does arise, however, about their importance as physiological or pathological processes.
A second difficulty of interpretation arises from the complex inter-relation of mechanisms by which angiotensin might influence arterial pressure. There are at least six of these. As a blood-borne hormone, angiotensin I1 may raise arterial pressure rapidly by direct vasoconstriction; also, at lower plasma concentration, it may raise blood pressure gradually by a different mechanism, probably involving the autonomic nervous system (Brown et al., 1981) . Another possibility is that blood-borne renin may enter the vessel wall producing angiotensin I1 locally in an amount sufficient to cause vasoconstriction (Swales, 1979) . Renin is also synthesized in blood vessels other than the afferent glomerular arteriole [endopIasmic reticulum stains by immunoperoxidase in some such vessels (Lindop et a]., 1983)] and here again it might generate angiotensin I1 locally (Swales, 1979) . Aldosterone excess raises blood pressure and as angiotensin I1 stimulates aldosterone secretion an increased circulating concentration of angiotensin I1 may increase blood pressure via an effect on aldosterone. It is widely believed that a change in the ability of arterial pressure to influence urinary sodium excretion (pressure natriuresis) is important in the long-term regulation of arterial pressure (Guyton et al., 1972) . Angiotensin in low dose alters pressure-natriuresis. Finally, there is a large but controversial literature on the possible pressor effects of angiotensin I1 generated locally within the brain.
Studies in which angiotensin I1 is infused in normal subjects suggest that the plasma concentration of endogenous peptide is close to a range in which it influences arterial pressure as a blood-borne hormone (Brown et al., 1979) . In patients with renin-secreting tumours high values are found and it is certain that these are responsible for the elevation of arterial pressure. Increased plasma angiotensin I1 concentration can cause persistent hypertension, therefore. There is also an elevation of plasma angiotensin I1 concentration in patients with renal artery stenosis, but the elevation is less consistent and the evidence implicating renin and angiotensin in pathogenesis is less certain (Brown et al., 1979) .
Renin inhibitors and blood pressure
Each step in the sequence renin -.+ angiotensin I -.+ angiotensin I1 -.+ receptor can be inhibited competitively. We are concerned here with inhibitors of renin. As is described in more detail by Veber et al. (1984) in this Colloquium there are now several highly potent inhibitors of renin. Szelke et al., (1982a, 1983) have synthesized a series of inhibitors which are analogues of the transition state of reninsubstrate (Table 1 ). The affinity of a protease for the transition state of its substrate is greater than its affinity for the unmodified substrate (Hofmann, 1974) . Analogues of reninsubstrate were therefore designed to imitate this transition state. With a reduced isostere, statine, or a hydroxy isostere in the cleavage site large increases of inhibitory potency were produced (Table 1 ). The most potent inhibitor so far is the hydroxy isostere (Table 1) .
Renin inhibitors are enzyme-specific. (Fig. 1) . The fall of Table 1 . Five inhibitors of renin based on the N-terminal sequence of human renin substrate H.112 is the unmodified octapeptide which has a small inhibitory capacity when assessed as the concentration of inhibitor needed to reduce the activity of renin in standard plasma by 50% (I(&) . A large increase of potency results from introduction of a reduced isostere in H. 113. Statine substitution for leucine in H. 176 produced a further increase. The most potent inhibitors were those with a hydroxy isostere with and without the protective group BOC. 
Conclusions
Our main conclusions from these and earlier studies (Brown et al., 1979) are that angiotensin I1 circulates in plasma at a concentration capable of influencing arterial pressure, partly by direct vasoconstriction and probably also by a slower-developing mechanism. Renin is also present in blood vessels and in the brain, but these tissues are less accessible than blood for analysis which may be the reason why knowledge of the role of extravascular renin is less well advanced. Meanwhile, we conclude that Tigerstedt & Bergman (1898) were correct: renin is released from the kidney into blood and it is a blood-borne chemical messenger producing an effect at a distance by acting (indirectly via angiotensin 11) on blood vessels. Although correct theirs is unlikely to be the whole story. 
Biochemistry of renin

PuriJication
Lack of a pure preparation of renin was one of the major obstacles to the progress of research on the renin-angiotensin system and high blood pressure. Successful purification of renin initiated a spectacular development of renin research. The purification of renin in the early stage was attained by the application of an affinity-chromatographic technique employing pepstatin as an affinity ligand. Pepstatin had been found to inhibit acid proteases strongly and renin with a moderate K, value. This moderate affinity of pepstatin to renin turned out to be ideal for the affinity chromatography. Use of protease inhibitors was essential in obtaining stable preparations of renin from kidneys (Murakami & Inagami, 1975; Yokosawaetal., 1979) . Renin was also purified by conventional chromatographic methods from mouse submandibular gland which is rich in renin (Cohen et al., 1972; Misono et al., 19826) . Renin from this gland was found to immunologically cross-react with mouse kidney renin. Renin was found in other tissues as well. Hirose eta/. (1982) obtained it in a homogeneous state from bovine pituitary by a 1.6 million-fold purification. Recently interesting new affinity ligands have been developed from studies of specific synthetic inhibitors of renin (Szelke et al., 1982) .
Properties
Renin is a monomeric enzyme with an approximate M, of 36000. It has the specific function of cleaving the decapeptide angiotensin I from the N-terminal region of the prohormone angiotensin. It has no general protease activity (Misonoetal., 19826) . Tocharacterize the active site of such a unique enzyme with a stringent substrate specificity, group-specific reagents were employed for the chemical modifications of catalytically essential groups. Selective modification of a carboxyl group by DAN and stoichiometric loss of renin activity revealed the involvement of a catalytically essential /karboxyl group of an aspartyl residue (Misono & Inagami, 1980) in analogy with acid proteases (Bayliss et al., 1969) . Inactivation of renin by EPNP and the finding that inactivation by DAN and E P N P occurred in a mutually independent manner indicated a second carboxyl group which is essential for renin action (Misono & Inagami, 1980) . Such a residue was also found in acid proteases such as pepsin (Tang, 1971; Hartsuck & Tang, 1972) . Using tyrosine-specific (tetranitromethane, acetylimidazole and diazonium-l-tl-tetrazole) and arginine-specific (phenylglyoxal) reagents we * Abbreviations used : DAN, diazoacetyl-D,L-norleucine methyl ester; EPNP, 1,2-epoxy-3-(nitrophenoxy)propane; cDNA, complementary DNA.
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have also shown the involvement of two tyrosyl residues and one arginyl residue in the active site of renin. These results indicated a close similarity of renin with acid proteases in its active site structure.
Amino acid sequence
Determination of the amino acid sequence of mouse submandibular gland renin further confirmed the close structural similarity of renin and acid proteases. This renin was found to consist of one heavy chain with 288 amino acid residues and one light chain with 48 residues connected by a disulphide bridge (Misono et a/., 1982a) . Its amino acid sequence determined by Edman degradation (Misono et al., 1982a) or that deduced from the nucleotide sequence of its cDNA (Panthier et al., 1982) and human renin sequence similarly deduced from its cDNA nucleotide sequence (Imai et al., 1983) showed greater than 40% sequence identity with porcine pepsin (Sepulveda et a/., 1975) or bovine chymosin (Foltman & Pedersen, 1977) . A greater than 20% homology was observed even with the fundal enzymes such as penicillopepsin ( Hsu et al., 1977) . Noteworthy is the conservation of long sequences of amino acids in the vicinity of the two catalytically essential amino acid residues Asp-32 and Asp-215 (Fig. la) . Amino acid residues in the vicinity of Tyr-75, Trp-190 and Arg-308 are also well conserved among the acid proteases and renin (Fig. lb) , indicating the essential nature of these residues in support of the observations made in the chemical modification studies. A degree of similarity between renin and acid proteases also seems to exist in their tertiary structures which are largely determined by amino acid sequence since the co-ordinate of the three-dimensional structure of a fungal acid protease endothiapepsin accommodates the amino acid residues in the renin structure (Blundell et al., 1983) .
While renin and acid proteases share several common features, the restricted substrate specificity and neutral pH optimum distinguish renin from acid proteases. The stringent substrate specificity must be due to selective subsite interactions involving up to seven subsites since renin requires a substrate structure consisting of a minimum of six or seven amino acid residues. The structure of the subsites has not been identified. The structural basis for the neutral pH optimum has not yet been identified either. The amino acid sequence deduced from the nucleotide sequences of the cDNA of mouse renin (Panthier er al., 1982) and human renin (Imai et al., 1983) contains the sequence of the signal peptide and activation peptide. Based on the N-terminal structure of active renin and on postulated signal peptide sequences, the pro-sequence or potential activation peptide sequences were deduced (Corvol et al., 1983; Imai et al., 1983) as shown in Fig. l(a) . The conspicuous lack of homology (less than 10%) between the activation peptides of the renin zymogen and pepsinogen suggests different mechanisms of activation for renin and acid proteases (Corvol et al., 1983) . The presence of paired basic amino acids -Lys-
